RESUMEN
OBJECTIVE:To evaluate the efficacy of exosomes derived from mesenchymal stem cells on animal models of acute liver failure. METHODS:PubMed,Web of Science,Embase,The Cochrane Library,CBM,CNKI,WanFang,and VIP databases were retrieved from inception to January 16,2023.A series of animal experiments on the treatment of acute liver failure animal models by exosomes derived from mesenchymal stem cells were collected.Two evaluators screened the literature and extracted the data independently.The bias risk was evaluated by the SYRCLE tool.The extracted data were analyzed by Revmen 5.4.1 software and Stata 17.0 software. RESULTS:A total of 241 articles were retrieved and 9 animal experiments were included,with 219 animals:110 animals in the model group and 109 animals in the exosome group.The results showed that the survival rate of animals in the exosome group improved significantly[RR=9.34,95%CI(3.91,22.29),P<0.001],the levels of serum alanine transaminase[SMD=-5.31,95%CI(-7.43,-3.19),P<0.001]and aspartate aminotransferase[SMD=-4.47,95%CI(-5.85,-3.10),P<0.001]were reduced obviously.The expressions of interleukin-1β[SMD=-11.54,95%CI(-18.12,-4.95),P=0.000 6],interleukin-6[SMD=-5.75,95%CI(-8.08,-3.41),P<0.001]and tumor necrosis factor-α[SMD=-4.46,95%CI(-6.83,-2.09),P=0.000 2],were suppressed obviously. CONCLUSION:Exosomes derived from mesenchymal stem cells effectively inhibit the inflammatory response,ameliorate liver function of animals with acute liver failure,and improve their survival rate.The results of subgroup analysis showed that the shorter survival time of animals(≤24 hours),the lower dose of transplanted exosomes(<1 mg/kg)and the source of exosomes(adipose-derived mesenchymal stem cells)may affect the efficacy of the exosomes derived from mesenchymal stem cells in the animal model of acute liver failure.This conclusion and its clinical transformation still need to be confirmed by randomized controlled studies with large sample sizes and high quality.
RESUMEN
In order to avoid the intra- and post-operative risks caused by massive blood loss, there are various clinical methods for evaluating the blood supply of the tumor and the distribution of blood vessels around the tumor before surgery, such as dynamic enhanced CT, dynamic enhanced magnetic resonance imaging, digital subtraction angiography, etc. And there are a variety of pre- and intra-operative methods to reduce tumor bleeding, such as transarterial vertebral tumor embolization, percutaneous or transpedicular injection of Onyx/NBCA, antifibrinolytic drugs, controlled deliberate hypotension, etc. This article reviews on spinal tumor blood supply assessment and the methods to reduce the amount of surgical bleeding.
RESUMEN
ObjectiveTo investigate the pharmacokinetic effects of baicalin on cerebral ischemia-reperfusion (I/R) after iv administration in rats.MethodsThe cerebral I/R rats were induced by occluding the bilateral carotid arteries of normal rats for 2 h,followed by reperfusion.The resultant animals were immediately iv administrated with baicalin (90 mg/kg),whilst the same dose of baicalin was injected to the normal rats.Plasma samples were collected at different time to construct pharmacokinetic profiles by plotting drug concentration vs time.Quantification of baicalin in rat plasma was achieved using a simple and rapid HPLC method.ResultsIn normal rats,the major parameters of distribution half-life,elimination half-life,area under the plasma concentration-time (AUC),apparent volume of distribution (Vd),and clearance (CL),estimated by an open two-compartmental model,were 0.8868 min,26.0968 min,149.6204 mg/min·L,4.765 L/kg,and 0.5776 L/kg·min),respectively.However,in I/R rats,the corresponding parameters were 2.084 min,34.4998 min,260.0188 μg.min/L,5.9376 L/kg,and 0.334 L/(kg·min),respectively.ConclusionThe cerebral I/R could significantly increase AUC and Vd values,decrease CL values,and prolong the terminal half-life of baicalin.These findings suggest that the injuries of I/R could play an important role in pharmacokinetic process ofbaicalin.